Alvotech Ordinary Shares (ALVO)
Price trend is one of its highest-scoring factors.
ALVO scores higher than 86% of the 1,101 tickers we compare it with (Health Care).
As of 10 October 2026, Alvotech Ordinary Shares (ALVO) scores 61 out of 100 on the Market Census six-factor composite, which puts it at the Above average score level. The score is made from six named factors: price trend, strength vs the market, company finances, insider trades, market mood and recent momentum. It records what they read on 10 October 2026, and it is not investment advice.
Updated · scores usually change about once a day
Key statistics
Market fields as reported. An em-dash means we hold no value for this ticker — most of the universe has no daily price or volume read.
- Relative volume
- 0.61× 30-day average
- 52-week range
- 2.94 – 9.04
- Market cap
- $2.29B
- Earnings date
- 11 Nov 2026
- Volume
- 707,139
- Avg. volume (30d)
- 1,163,277
- Open
- 5.67
- Previous close
- 5.67
- Day's range (regular session)
- 5.57 – 5.80
The last trade can be an extended-hours trade, so it can sit outside the regular-session range.
Shown without a peer ranking — we hold no percentile for these yet, so there is nothing here to locate them against.
- Beta
- 0.23
- P/E (TTM)
- —
- EPS (TTM)
- -0.63
Score breakdown · six named factors
Each bar is one part of the score, from 0 to 100. Read what the score means.
What the score says about ALVO right now
Alvotech Ordinary Shares (ALVO) currently scores 61/100 on the Market Census six-factor composite, at the Above average score level. ALVO is +1.94% on the day and +6.06% over five sessions as of the most recent tick. Above average sits a bit above the middle. The data for ALVO leans good, with some weak spots. ALVO's strongest factor is price trend at 82/100 — a very strong read on which way the price has been going. The weakest factor is company finances at 47/100 — middling company numbers. A low company-finances reading is the canonical "value trap" warning: technical setups on broken fundamentals don't tend to compound.
Generated from the six-factor breakdown above. Changes when the underlying scores do, usually about once a day. More on what the score means.
See ALVO in the scanner
This page is free to read with no account at all. Signing up takes an email and a password: a free account runs the scanner on the top 10 scored rows of any scan, keeps one saved screen, a 5-ticker watchlist, and opens 12 ticker detail pages a day. The card is what starts a 30-day Premium trial — $0 that day, then $19.99/month from day 30, cancel online any time before then — and that is what turns on every matching row instead of the first 10, alerts, the 200-ticker watchlist and recent insider buys (SEC Form 4).
Recent ALVO news
Latest headlines that name Alvotech, one per story, sourced from Market Census’s news feed (Polygon/Massive + Finnhub).
- Alvotech and LOTTE Biologics announce US-based manufacturing agreement to increase global supplyYahoo
- Alvotech And LOTTE Biologics Announce Long-Term Strategic Manufacturing Partnership For Biosimilar ProductsBenzinga
- Alvotech Soars 13% on FDA Nod That “Effectively Doubles” US Humira Biosimilar CapacityYahoo
- Alvotech stock surges after FDA manufacturing approvalYahoo
- FDA approves additional U.S. manufacturing capacity for SIMLANDI®, Alvotech’s biosimilar to Humira®Yahoo
We hide 7 more that told readers to buy or sell, or gave a price target.
Saved snapshot; the news and prices on this page can be an hour old or more.
Similar setups in Health Care right now
Six health care tickers whose composite scores are closest to ALVO’s 61, all within 1 point.
Sorted by closeness to ALVO’s composite score within Health Care. Saved snapshot; can be an hour old or more. Run the full scanner →
Prices delayed about 15 minutes; scores usually change about once a day. Not investment advice — see risk disclosure.